Update on License Agreement between Meda and Valeant

Meda out-licensed its dermatological products Elidel and Xerese to Valeant in North America in 2011. Elidel is a patented prescription product for the treatment of atopic dermatitis. The license agreement followed a decision by Meda to focus on the Respiratory area with its sales force in the US. Meda is entitled to royalties based on net sales of these products and Zovirax. For 2015 the royalties amount to USD 40 million, less than 2% of Meda's expected net sales. For 2016 and onwards the agreement stipulates lower royalties for Meda, for the next year expected to be about half the amount of this year. Going forward, the agreement is with less than 1% of Meda's net sales of minor importance to Meda overall.

Since Elidel and Xerese are out-licensed with all commercialization rights, Meda has no insight into Valeant's distribution channels and how the out-licensed products are distributed. However, according to information received from Valeant, less than 20% of sales of the licensed products have been distributed through Philidor.

In 2014 Meda decided to terminate the joint venture companies with Valeant in Canada, Mexico and Australia.

Anders Lönner, who is on the board of Valeant, left Meda in October 2013 and has no function at Meda since then.

The expected decrease in royalties from Valeant in 2016 will not have any impact on Meda's potential M&A activities.

Meda AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 16, 2015, at 07:00 CET.

MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit www.meda.se.

This information was brought to you by Cision http://news.cision.com

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.